Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / VEGFA

VEGFA

Basics

Aliases:
This biomarker is also known as:
  • vascular endothelial growth factor,
  • VEGF-A,
  • Vascular permeability factor,
  • vascular endothelial growth factor A,
  • VEGF,
  • VPF,
  • MVCD1,

View in BioMuta

Description…

Vascular endothelial growth factor (VEGFA or VEGF) is a growth factor and signaling protein involved in the regulation of angiogenesis, vasculogenesis, and endothelial cell grown. It induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Three VEGFR isoforms have been identified in humans; VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4). VEGFR-2 mediates the majority of cellular responses to VEGF. VEGFR-1 is thought to modulate VEGFR-2 signaling or to act as a dummy/decoy receptor to sequester VEGF away from VEGFR-2.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: VEGFA

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

Preclinical and clinical studies have suggested that VEGFA is important in human breast cancer.

Performance Comment

VEGFA was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Lung

Attributes

Phase: Two
QA State: Under Review

Overview

Elevated levels of VEGFA in serum and tumor tissue are associated with poor prognosis in patients with lung cancer.

Performance Comment

Levels of angiogenic markers FGF2, ANG, and VEGFA in exhaled breath condensate significantly discriminated between 17 individuals with newly detected non-small cell lung cancer versus stable and exacerbated chronic obstructive pulmonary disease (COPD).

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.